Could CSL shares capitalise on the next pandemic?

While CSL didn't see its share price explode like some vaccine makers, the company was hard at work to combat the coronavirus.

| More on:
woman getting the Covid 19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares gained global attention amid the COVID pandemic
  • CSL Seqirus has been contracted to deliver an avian flu vaccine candidate for a clinical study in the United States
  • The company’s US-based Holly Springs facility is prepared to make 150 million vaccine doses within the first six months of an outbreak

CSL Limited (ASX: CSL) shares weren't immune to the initial stock market panic that unfolded in the face of the COVID-19 pandemic.

In the month-long sell-off from late February 2020 through to late March 2020, the S&P/ASX 200 Index (ASX: XJO) global biotech company fell by some 20%.

Over the following month, CSL shares quickly recouped those losses.

While CSL didn't see its share price explode like some vaccine makers, the company was hard at work to combat the coronavirus.

In an agreement with AstraZeneca, CSL committed to manufacturing around 50 million doses of vaccines in Australia for domestic supply. The first doses were delivered in March 2021.

Which begs the question, could CSL shares capitalise on the next pandemic?

What's this about the avian flu?

Before ploughing ahead, our apologies for even throwing out the words 'next pandemic'. There's no need to go hoarding toilet paper and long-life milk just yet. Or hopefully ever again!

But that doesn't mean governments and biotech firms aren't working to get ahead of any potential future outbreaks.

As Fierce Pharma reports, CSL Seqirus – a subsidiary of CSL – inked a $30.1 million agreement with the Biomedical Advanced Research and Development Authority (BARDA), a branch of the United States Department of Health and Human Services.

The agreement will see CSL deliver an avian flu vaccine candidate for a clinical study.

There have only been a few reported cases of the avian flu being transmitted from a bird to a person. And no reported cases of human-to-human transmission yet.

However, Lorna Meldrum, VP of commercial operations, international and pandemic response at CSL Seqirus, said BARDA is concerned enough about the potential dangers of the avian flu to fund the research.

"The next pandemic is probably going to be an influenza pandemic," Meldrum said. She noted that CSL Seqirus has partnerships with BARDA and other government health agencies across the globe.

Meldrum said that if there was another pandemic outbreak, CSL's seasonal flu shot production at its Holly Springs plant in North Carolina would "immediately switch" over to producing the pandemic influenza vaccine. She said the plant would be prepared to make 150 million doses within the first six months.

Addressing the company's readiness at its Holly Springs facility, Meldrum said (quoted by Fierce Pharma):

We have all the ingredients that you need to make a flu vaccine. We have a trained workforce. We have all our [standard operating procedures] in line; we have all our regulatory documents. So, we're like a machine that you just flick the switch, and then we're up and running.

How have CSL shares been performing?

The CSL share price has slipped 6.3% in 2022. That compares to a year-to-date loss of 12.4% posted by the ASX 200.

Longer-term, CSL shares are up 101% over five years.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »